Market Research Blog – Page 845 – New Product Development

Global Acrocallosal Therapeutics Market to Reach USD 412.4 Million by 2033, Growing at a 10.8% CAGR

Acrocallosal Syndrome Therapeutics Market

The global Acrocallosal Therapeutics Market is currently valued at USD 147.9 million in 2023 and is projected to witness substantial growth over the next decade. With a robust compound annual growth rate (CAGR) of 10.8% from 2023 to 2033, the market is expected to reach an impressive valuation of USD 412.4 million by 2033.

This remarkable growth is largely driven by technological advances in healthcare, which have significantly improved diagnostic capabilities and treatment options for rare genetic disorders such as acrocallosal syndrome. The disorder, a rare congenital condition, often requires specialized therapies and care, creating a growing demand for advanced therapeutics in this market.

Key Market Insights:

Market Value in 2023: US$ 147.9 million
Projected Market Value by 2033: US$ 412.4 million
CAGR (2023-2033): 10.8%

Technological innovations in the healthcare industry, including gene therapies, personalized medicine, and advanced diagnostic tools, have enhanced treatment outcomes for patients with rare genetic conditions. These advancements are playing a critical role in expanding the acrocallosal therapeutics market, offering patients more targeted and effective treatment options.

As awareness and diagnosis of acrocallosal syndrome improve, the demand for novel treatments is expected to rise. Key industry players are investing heavily in research and development to introduce breakthrough therapies that address the underlying causes of the condition, further fueling market growth.

Acrocallosal syndrome is a rare condition also called agenesis of the corpus callosum. Agenesis of the corpus callosum occurs when the tissue that connects the left and right halves of the brain (the corpus callosum) fails to form normally during the early stages of development before birth.

Other brain abnormalities, including the growth of large cysts in brain tissue, have also been reported in people with acrocallosal syndrome. The changes in brain structure associated with this condition lead to delayed development and intellectual disability, which is most often moderate to severe. Some affected individuals also experience seizures.

Competitive Landscape

Arena Pharmaceuticals, Artery Therapeutics, Athera Biotechnologies, Bayer AG, Cardiome Pharma Corp., Cerenis Therapeutics Holding SA, Esperion Therapeutics, GlaxoSmithKline Plc, Lee’s Pharma Corp., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Vitae Pharmaceuticals, Inc. are some of the key players in the acrocallosal syndrome therapeutics industry.

The manufacturers are involved in the production of acrocallosal syndrome therapeutics in a larger capacity. Research and innovation are also conducted to launch innovative products for acrocallosal syndrome therapeutics.

Also, some of the key players are acquiring small pharmaceutical companies to increase their production capacity. Suppliers are focusing on expanding their market presence across the world by initiating new product launches and boosting sales.

In August 2022, Esperion announced that bempedoic acid (NEXLETOL®) is now recommended as an important oral non-statin therapy for LDL-cholesterol (LDL-C) lowering in the management of atherosclerotic cardiovascular disease (ASCVD) by the American College of Cardiology (ACC) task force on expert consensus decision pathways (ECDP).
In October 2022, GlaxoSmithKline plc and Tempus entered into a three-year collaboration agreement that provides GSK with access to Tempus’ AI-enabled platform, including its library of de-identified patient data. Through its leading Artificial Intelligence and Machine Learning (AI/ML) capability, GSK will work together with Tempus to improve clinical trial design, speed up enrolment and identify drug targets. This will contribute to GSK’s R&D success rate and provide patients with more personalized treatment faster.

Key Companies Profiled

Arena Pharmaceuticals
Artery Therapeutics
Athera Biotechnologies
Bayer AG
Cardiome Pharma Corp.
Cerenis Therapeutics Holding SA
Esperion Therapeutics
GlaxoSmithKline Plc
Lee’s Pharma Corp.
Pfizer Inc.
Teva Pharmaceutical Industries Ltd.
Vitae Pharmaceuticals, Inc.

A Full Report Overview

Key Segments Covered in the Acrocallosal Syndrome Therapeutics Market Industry Survey

Acrocallosal Syndrome Therapeutics Market by Type:

Losmapimod
Praluent
Evolocumab

Acrocallosal Syndrome Therapeutics Market by Syndromes:

ST Elevation Myocardial Infarction,
non-ST Elevation Myocardial Infarction,
Unstable Angina

Acrocallosal Syndrome Therapeutics Market by Route of Administration:

Injectable
Oral

Acrocallosal Syndrome Therapeutics Market by Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Bamboo Packaging Market Projected to Reach USD 950.3 Million by 2033, Driven by Sustainability Trends

The global bamboo packaging market is on track for substantial growth, with an estimated valuation of USD 511 million in 2023 and projected to reach USD 950.3 million by 2033, expanding at a CAGR of 6.4%. As sustainability becomes a core focus for industries worldwide, sales of bamboo packaging are expected to increase significantly, with the top five providers contributing approximately 25-30% of revenue share in 2022.

Market Insights and Trends
According to Future Market Insights (FMI), the bamboo packaging market was valued at USD 480.3 million in 2022. The cups and straws segment is anticipated to command around 24% of the market share by the end of 2033, driven by the growing demand from food service providers and the increasing preference for sustainable packaging solutions. This segment’s growth reflects a broader trend toward eco-friendly alternatives in the packaging industry.

The bamboo packaging market is forecasted to create an incremental growth opportunity of USD 414.8 million during the upcoming years, showcasing the robust demand for environmentally-friendly packaging options.

Core Concepts in the Bamboo Packaging Industry

Current Market Value: In 2023, the bamboo packaging market is valued at US$ 511 million.
Future Market Size: By 2033, the market is projected to surpass US$ 950.3 million.
CAGR Prediction: The bamboo packaging market is expected to grow at a CAGR of 6.4% from 2023 to 2033.
Top Profitable Countries: India and China are the primary countries showing notable profitability potential for bamboo packaging.
Historical Growth: From 2018 to 2022, the market grew at a 4% CAGR, reaching US$ 480.3 million by the end of 2022.

Market Insights

The cups and straws segment is expected to dominate the bamboo packaging market, holding approximately 24% of the market value share by the end of 2033. This segment’s growth is driven by increasing demand from food service providers and the broader adoption of sustainable packaging solutions.

According to Future Market Insights (FMI), the bamboo packaging market totaled US$ 480.3 million in 2022. The market is expected to create an incremental growth opportunity of US$ 414.8 million during the forecast years, reaching US$ 950.3 million by 2033. The top three countries held around 35-40% of the global bamboo packaging market in 2022.

Key Market Insights:

Rise of Eco-Friendly Packaging Solutions: With the negative impact of plastic packaging on the environment becoming increasingly evident, the demand for sustainable packaging alternatives has surged. Bamboo, a natural and biodegradable material, has emerged as a preferred alternative to disposable plastics. Manufacturers are transitioning to bamboo packaging due to its eco-friendly properties and cost-effectiveness.

Advantages Over Plastic Packaging: Bamboo packaging offers numerous advantages over plastic, including biodegradability, cost-effectiveness, and easy availability. Bamboo production releases significantly more oxygen compared to other trees, contributing to reduced carbon footprints. Its versatility allows for the creation of various packaging products such as boxes, straws, pallets, and more, making it an ideal replacement for plastic packaging.

Growing Application in the Food & Beverage Industry: Packaging plays a crucial role in the food industry, ensuring food safety and protection from external contaminants. Bamboo packaging, with its biodegradable nature and excellent insulation properties, is gaining traction as an ideal solution for food packaging. From food containers to takeout containers, coffee cups, and straws, bamboo packaging offers a secure and eco-friendly packaging option without leaching harmful substances into the food.

Regional Opportunities: South Asia and East Asia are anticipated to be the most lucrative markets for bamboo packaging, driven by the easy availability of bamboo material and its rising applications in various industries such as food & beverage and cosmetics & personal care. The market is expected to nearly double during the forecast period in these regions.

Growing Sustainability Concerns to Push Demand in the Market

Increasing environmental concerns have increased the preference for sustainable packaging across the globe. Consumers are becoming more aware of the effects of plastic and single-use packaging on the surroundings. Bamboo packaging is a replacement for metal or plastic packaging as it grows without the need for pesticides.

Bamboo packaging can be composted easily and sustainability is in every process connected with the production. Hence, various manufacturers are also replacing plastic packaging with bamboo packaging to achieve sustainability. For instance, Dell has started using bamboo packaging to protect laptops. They have started using bamboo for interior cushioning. Thus, rising awareness regarding sustainability is fuelling the demand for bamboo packaging.

Further, government organizations are also providing support to bamboo packaging manufacturers. According to the report by the International Bamboo and Rattan Organisation, in 2021, various representatives from government and non-government organizations took part in the event to discuss bamboo as an alternative material to plastic.

China’s recent policies saw restrictions and a ban on the import of plastic waste. China is ready to replace plastic with bamboo packaging. Thus, various efforts from the government and various other organizations are propelling the growth of the bamboo packaging market.

Bamboo Packaging Market Landscape

The key players operating in the global bamboo packaging market are HuhtamakiOyj, APackaging Group., Pi Sustainable Packaging Co., Ltd., Bloom Eco Packaging Co., Ltd., Golden Arrow, Inc., and Three Bamboo. Also, some of the other noticeable players in the market are Xiamen HBD industry & trade CO., LTD, Meysher Industrial Group, Sunkea, GUANGZHOU HUIHUA PACKAGING PRODUCTS CO. LTD, Ningbo Willest International Trading Co., Ltd., Yiwu Cool Commodity Co., Ltd., BeGreen Packaging, Bio Transito SAS Ltd, and others.

Access Full Report: https://www.futuremarketinsights.com/reports/bamboo-packaging-market

Global Bamboo Packaging Market by Category

By Pulp Type:

Recycled Pulp
Virgin Pulp

By Packaging Type:

Cups & Straws
Bottles & Jars
Boxes & Cartons
Clamshell
Tubes
Mailers
Barrels
Crates
Pallets
Others (Bowls, Plates, etc.)

By End Use Industry:

Foods & Beverages
Pharmaceuticals
Cosmetics & Personal Care
Electrical & Electronics
E-Commerce
Automotive
Agriculture

By Region:

North America
Latin America
Europe
South Asia
East Asia
The Middle East & Africa
Oceania

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer, Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Join us as we commemorate 10 years of delivering trusted market insights. Reflecting on a decade of achievements, we continue to lead with integrity, innovation, and expertise.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Adrenogenital Syndrome Treatment Market to Reach USD 22.08 Billion in 2033, Driven by New Therapies and Minimally Invasive Surgeries

The global Adrenogenital Syndrome Treatment Market is expected to achieve significant growth, reaching a market value of USD 12.81 billion in 2023. With a compound annual growth rate (CAGR) of 5.6% from 2023 to 2033, the market is poised to expand further as innovative treatments and advanced medical procedures continue to gain traction.

The increasing adoption of natural treatments, minimally invasive surgeries, and new therapies is anticipated to be the primary growth driver for the market. These approaches offer more effective and less invasive solutions for patients, improving outcomes and quality of life for those affected by adrenogenital syndrome, also known as congenital adrenal hyperplasia (CAH).

Key Market Insights:

Market Value in 2023: US$ 12.81 billion
CAGR (2023-2033): 5.6%

Adrenogenital syndrome is a genetic disorder affecting the adrenal glands, often requiring lifelong management and treatment. The rising focus on developing therapies that reduce complications and improve the ease of managing this condition is expected to play a crucial role in expanding the market. The development of advanced therapeutic interventions, such as hormone replacement therapy (HRT) and gene-based treatments, is likely to further accelerate market growth in the coming years.

The increasing prevalence of genetic testing and early diagnosis also supports the growth of the adrenogenital syndrome treatment market. As awareness about the condition and its treatments grows, patients are gaining access to more effective and personalized treatment options.

Surgically fixing abnormal genital appearances is further expected to enhance the market. Hormonal therapy is also used to replace the hormones that are not produced by the adrenal glands. On a daily basis, patients with chronic atopic diseases are administered corticosteroids or hydrocortisone. As a result of this treatment, the production of androgen will be normalized.

As this syndrome is highly prevalent among children and infants, the market is expected to substantially grow in the coming years. In the early stages of the condition, infants are injected with hormones, with the transition to orally administered hormones after 18 months. CAH patients who receive treatment are most likely to live a normal life. The survival rate for infants without treatment is usually less than six weeks.

Market Competition

Strategic partnerships can boost revenue and market share for manufacturers by increasing production and meeting consumer demands. To ensure that end users are able to benefit from the use of new products and technologies, you must promote them to end users. By forming a strategic partnership, a company can increase the amount of production it can do as a result of an increase in its capacity.

Spruce Biosciences Inc. and Kaken Pharmaceutical Co. Ltd announced a licensing agreement to develop and commercialize Spruce’s product candidate, tildacerfont, for treating congenital adrenal hyperplasia (CAH). Spruce will receive a $15 million upfront payment from Kaken as part of the agreement, and additional payments are pending upon reaching future development and commercial milestones. In addition to that, tiers of double-digit royalties will be paid on Japanese net sales. For all other geographies, Spruce will retain all rights to tildacerfont, while Kaken will develop and market it in Japan.
A new Phase 2 study from Neurorocrine Biosciences, Inc. is being presented demonstrating substantial reductions in adrenal androgens and androgen precursors in adolescent patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency (21-OHD). As part of its presentation in Hall A1, the company also provided information regarding patient preferences and treatment patterns for classic CAH.

Key Companies Profiled

Crystal Pharma
Monarch Pharmaceuticals, Inc.
Jubilant Cadista Pharmaceuticals Inc.
Pfizer CentreOne
Healthkey Lifescience Pvt. Ltd.
Zydus Pharmaceuticals
Praxgen Pharmaceuticals
Sandoz
Vintage Labs
Actavis, Inc.

A Full Report Overview

Key Segments Profiled in the Adrenogenital Syndrome Treatment Market Industry Survey

By Drug Type:

Mineralocorticoids
Glucocorticoids

By Route of Administration:

Oral
Parenteral
Intravenous
Inhaled
Others

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Others

By Region:

North America
Latin America
Europe
Asia Pacific
Middle East & Africa

Author By:

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Alcohol Use Disorder Treatment Market to Reach USD 1,300 million by 2033 at a 6.4% CAGR, Driven by Rising Incidence of Alcohol Abuse

The global Alcohol Use Disorder Treatment Market is projected to experience substantial growth over the coming decade, with market value expected to rise from USD 700 million in 2023 to USD 1.300 Million by 2033, at a robust compound annual growth rate (CAGR) of 6.4%.

This growth is primarily driven by the rising incidence of alcohol abuse and binge drinking across the globe, as these issues continue to impact individuals regardless of age or gender. The increasing awareness surrounding alcohol use disorder (AUD) and its far-reaching consequences has led to a greater demand for effective treatment options, further propelling market expansion.

Key Market Insights:

Market Value in 2023: US$ 700 million
Projected Market Value by 2033: US$ 1.3 billion
CAGR (2023-2033): 6.4%

Alcohol use disorder is a widespread and serious condition that affects millions of people worldwide. Its non-discriminatory nature creates a substantial and growing market for treatments, including therapies, medications, and counseling services. The rise in public health initiatives and government programs aimed at addressing alcohol addiction is expected to further support the industry’s growth in the coming years.

The global market is also seeing advancements in the development of new and more effective treatments, offering promising solutions for those seeking recovery from alcohol dependence. Innovations in medication-assisted treatment (MAT) and behavioral therapies are likely to improve the success rates of treatment programs, contributing to the long-term expansion of the alcohol use disorder treatment market.

Several countries have seen an increase in patient awareness, an increase in treatment-seeking frequency, increased government participation, and a greater emphasis on addiction prevention as a result of drug awareness campaigns and accompanying preventative programmes. To communicate knowledge, television advertising, newspapers, information pamphlets, and other forms of media are used, all of which aid in market expansion. As The number of people effectively treated for AUD is increasing as a result of new drugs that prevent deterioration while also managing alcohol urges.

Each year, over 30,000 people die in the United States as a result of liver cirrhosis, the vast majority of which are caused by alcohol consumption. North America dominates the market for AUD treatment due to the availability of treatment drugs and a well-developed health infrastructure. Since India and China are the world’s two most populous countries, Asia Pacific has the highest population density. The Asia-Pacific region is expected to grow at a high rate from 2023 to 2033, owing to an increase in vulnerable adult population and increased demand for AUD treatment.

Key Takeaways from the Market Study

According to FMI, the worldwide Alcohol Use Disorder Treatment market would grow at a 6.4% value CAGR by 2033.
The global Alcohol Use Disorder Treatment market is expected to be worth US$ 700 million.
The global Alcohol Use Disorder Treatment market is anticipated to be worth US$ 1,300 million.
Europe is expected to be the most profitable region for Alcohol Use Disorder Treatment market growth.
North America is predicted to increase at a CAGR of 6.2% between 2023 and 2033.
According to Future Market Insights, Asia Pacific is predicted to develop at a CAGR of 6% from 2023 to 2033.
The alcohol abuse segment is expected to hold the largest market share for Alcohol Use Disorder Treatment in the forecast period 2023 to 2033.

“Drug awareness programmes and addiction & recovery facilities among the people are considerably contributing to market growth. One of the most important aspects of the development of the Alcohol Use Disorder Treatment industry is the use of awareness campaigns and associated anticipatory programmes,” says an analyst at FMI.

Market Competition

Prominent players in the Alcohol Use Disorder Treatment market are Alkermes, Teva Pharmaceutical Industries Ltd., BioCorRx, Inc., Adial Pharmaceuticals, ADDEX THERAPEUTICS, Kinnov Therapeutics, Opiant Pharmaceuticals, Omeros Corporation, GlaxoSmithKline plc and Merck & Co. Inc.

BioCorRx Inc., a developer and provider of innovative treatment programmes for substance abuse and related disorders, announced a partnership with Government Plus LLC, a leading provider of private sector healthcare to veterans, in December 2022, to expand its Beat Addiction Recovery Programme across the country.
Opiant Pharmaceuticals Inc. announced in November 2022 that it has agreed into a final merger agreement with Indivior Inc, a subsidiary of Indivior PLC, to be acquired. Indivior will buy all of Opiant’s existing shares for $20.00 per share in cash at closing, plus contingent value rights (CVRs) reflecting potential further payments of up to $8.00 per share over a seven-year period if the acquisition is completed.

More Valuable Insights Available

Future Market Insights offers an unbiased analysis of the global Alcohol Use Disorder Treatment market, providing historical data for 2018 to 2022 and forecast statistics from 2023 to 2033.

A Full Report Overview

Key Segments:

By Disorder Type:

Alcohol Abuse
Alcohol Dependence
Alcohol Addiction
Alcoholism

By Treatment Type:

Medication
Therapy
Multidisciplinary Treatment

Author By:

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Biosensors Market Poised for Significant Growth, Projected to Reach USD 65.2 Billion by 2033 at a 9.5% of CAGR

The Biosensors Market reached a global size of USD 24.5 billion in 2022. With a robust compound annual growth rate (CAGR) of 9.5% projected from 2023 to 2033, the market is expected to witness significant growth, surpassing historical trends.

Medical biosensors are anticipated to be the highest revenue-generating segment within the biosensors market, with projections indicating a CAGR of over 10.5% during the forecast period. This growth is driven by the increasing demand for innovative and accurate diagnostic tools in healthcare, which are critical for enhancing patient care and treatment outcomes.

Key Market Insights:

Global Market Size (2022): US$ 24.5 billion
Projected CAGR (2023-2033): 9.5%
Expected Growth of Medical Biosensors: Over 10.5% CAGR

The rising prevalence of chronic diseases, combined with an aging population, is fueling the demand for advanced biosensing technologies. As healthcare systems continue to focus on personalized medicine and early detection, the role of biosensors in monitoring health conditions and providing timely interventions becomes increasingly vital.

Furthermore, technological advancements in biosensor development—such as miniaturization, improved sensitivity, and integration with digital health platforms—are expected to enhance the efficacy and usability of these devices, thereby driving market expansion.

As the biosensors market evolves, stakeholders are encouraged to invest in research and development initiatives to create innovative biosensing solutions that address emerging healthcare challenges.

Competitive Analysis

With the increased demand for biosensors, global manufacturers are accelerating and improving their manufacturing processes with cost-effective solutions. A few of the key players in the biosensors market include Bio-Rad Laboratories Inc., Medtronic, Abbott Laboratories, Biosensors International Group, Ltd., Pinnacle Technologies Inc., Ercon, Inc., DuPont Biosensor Materials, Johnson & Johnson, Koninklijke Philips N.V., LifeScan, Inc., QTL Biodetection LLC, Molecular Devices Corp., Nova Biomedical, Molex LLC, TDK Corporation, Zimmer & Peacock AS, and Siemens Healthcare.

Some of the recent developments of key Biosensors providers are as follows:

In January 2022, Roche and Sysmex signed a Global Business Partnership Agreement (GBP) to supply hematological diagnostic services. Using IT technology, the new cooperation aims to enhance clinical decision-making and consumer experience. This long-standing, fruitful collaboration is still going strong, offering hematological diagnostic improvements to labs all over the world.
In December 2020, Abbott announced that Health Canada has authorized FreeStyle Libre 2, its next-generation sensor-based glucose monitoring gadget, for adults and children (4 years and older) with diabetes.
In December 2020, Bio-Rad Laboratories announced an expansion of its marketing agreement jointly with Siemens Healthineers. Under the agreement, Bio-Rad will offer quality control products and Unity Quality Control data management solutions for Atellica Solution platforms of Siemens Healthineers.
In November 2020, Medtronic announced the release of InPen with real-time CGM data from Guardian Connect. InPen is the first and only FDA-approved smart insulin pen for those who need large numbers of injections on a daily basis (MDI).
In October 2020, Bio-Rad Laboratories announced that they would launch their CFX Opus 96 and CFX Opus 384 Real-Time PCR Systems, as well as BR.io, a cloud-based instrument connectivity and data management platform.

Similarly, recent developments related to the companies in the Biosensors market have been tracked by the team at Future Market Insights, which are available in the full report.

A Full Report Overview

Market Segments Covered in Biosensors Market Analysis

By Product Type:

Medical
- Cholesterol
- Blood Glucose
- Blood Gas Analyzer
- Pregnancy Testing
- Drug Discovery
- Infectious Disease
Food Toxicity
Bioreactor
Agriculture
Environment
Others

By Technology:

Thermal
Electrochemical
Piezoelectric
Optical

By End-Use:

Home Healthcare Diagnostics
PoC Testing
Food Industry
Research Laboratories
Security & Biodefense

By Region:

North America
Latin America
Europe
APAC
Middle East and Africa (MEA)

Author By:

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Babesiosis Treatment Market Set to Reach USD 1.98 Billion by 2033 at a 5.0% of CAGR

The global Babesiosis Treatment Market is anticipated to be valued at USD 1.21 billion in 2023, with projections indicating robust growth at a compound annual growth rate (CAGR) of 5.0% between 2023 and 2033. By the end of this forecast period, the market is expected to reach approximately USD 1.98 billion.

The growth of the Babesiosis Treatment Market can be attributed to ongoing advancements in drug development and biotechnology aimed at effectively treating babesiosis, a tick-borne disease caused by the Babesia parasite. As research and innovation continue to evolve in this field, the market is poised for significant expansion.

Key Market Insights:

Projected Market Value for 2023: US$ 1.21 billion
Expected Valuation by 2033: US$ 1.98 billion
CAGR (2023-2033): 5.0%

The increasing prevalence of babesiosis, particularly in regions with high tick populations, is driving the demand for effective treatment options. Healthcare providers are increasingly recognizing the importance of timely diagnosis and intervention, which further fuels market growth.

Moreover, the rising awareness among healthcare professionals and patients regarding the symptoms and complications associated with babesiosis is expected to enhance early detection and treatment outcomes. This growing focus on preventative care and effective management strategies is critical in combating the disease and improving patient quality of life.

As the Babesiosis Treatment Market continues to develop, stakeholders are encouraged to invest in research and development initiatives that can lead to innovative treatment solutions, ultimately addressing the unmet needs of patients affected by this disease.

According to the analysis of Future Market Insights, major factors such as an increase in the number of cases of Lyme disease, and the extensive possibility for the growth of antibiotics for curing patients having babesiosis are anticipated to fuel the growth of the babesiosis treatment market during the analysis period. For instance, International Lyme and Associated Disease Society (ILADS) recommends customized antibiotic treatment for the patients depending on their response to treatment, as Lyme disease is hard to diagnose, which results in persistent infection. However, the treatment of antibiotics cannot reduce the infection of Lyme disease, which in turn gives a wider scope for the development of ideal antibiotic treatment of babesiosis.

Additionally, in March 2018, the USA Food and Drug Administration approved the Imugen Babesia microti Arrayed Fluorescent Immunoassay (AFIA), for the detection of antibodies to Babesia microti (B. microti) in human plasma samples, as well as the Imugen Babesia microti Nucleic Acid Test (NAT), for the detection of B. microti DNA in human whole blood samples. These tests were intended to be used as donor screening tests on samples from individual human donors, including volunteer donors of whole blood and blood components, as well as living organ and tissue donors.

Key Companies Profiled

GlaxoSmithKline LLC
Amneal Pharmaceuticals LLC
Apotex
Glenmark
Hetero
Lupin
Camber Pharmaceuticals, Inc.
Galderma
Fresenius Kabi
About
Pfizer, Inc.
Taro Pharmaceutical Industries
Otto Pharmaceutical
Medpharma
Endure Medical
Huajin Pharmaceutical
Mylan Pharmaceutical Inc.
Tabuk Pharmaceutical
Aurobindo Pharma Ltd
Epic Pharma LLC.

A Full Report Overview

Key Segments Covered in the Babesiosis Treatment Industry Analysis

Babesiosis Treatment Market by Drug Type:

Branded
Generic

Babesiosis Treatment Market by Route of Administration:

Oral
Injectable
Others

Babesiosis Treatment Market by End-Users:

Hospitals
Academic Research Institutes
Home Healthcare
Others

Babesiosis Treatment Market by Distribution Channel:

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others

Babesiosis Treatment Market by Region:

North America
Europe
Europe
Latin America
Middle East & Africa

Author By:

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Klinefelter Syndrome Therapeutics Market Expected to Reach USD 1.85 Billion by 2033 at a 5% of CAGR

Global Klinefelter Syndrome Therapeutics Industry — Global Klinefelter Syndrome Therapeutics Market

The global Klinefelter Syndrome Therapeutics Market is projected to surpass USD 1.14 billion in 2023, with an anticipated compound annual growth rate (CAGR) of 5% from 2023 to 2033. By the end of this forecast period, the market is expected to reach an impressive valuation of USD 1.85 billion.

Klinefelter syndrome, also known as 47, XXY, is a genetic condition characterized by the presence of an extra X chromosome. This common chromosomal disorder affects approximately one in every 500 individuals, yet many remain undiagnosed. Symptoms of Klinefelter syndrome can vary widely among patients, with some experiencing no observable indications of the condition.

Key Market Insights:

Projected Market Value for 2023: US$ 1.14 billion
Expected Valuation by 2033: US$ 1.85 billion
CAGR (2023-2033): 5%

The increasing awareness of Klinefelter syndrome and its symptoms is expected to drive demand for effective therapeutics and diagnostic solutions. As healthcare providers become more knowledgeable about this genetic condition, more individuals are likely to seek diagnosis and treatment, contributing to market growth.

In addition to greater awareness, ongoing research into Klinefelter syndrome’s implications and the development of targeted therapies are also expected to fuel the market. The emphasis on personalized medicine and innovative treatment strategies will play a crucial role in enhancing patient outcomes and quality of life for those affected by this condition.

The initiative is part of broader incentives for all types of health check-ups, anticipated to be a driving force behind the market’s growth in the years to come. The surge in men’s fertility disorders, coupled with an increase in clinical symptoms across all age groups, is expected to play a pivotal role in stimulating market expansion.

Europe is expected to be the second-fastest-growing region in the industry. The rising prevalence of the disease has enhanced research financing, and health organizations such as the National Institutes of Health (NIH) are focusing on raising awareness about the syndrome, which is cruising market growth. North America is expected to dominate the market due to the region’s large number of testosterone drugmakers, as well as increased awareness among the region’s population. In addition, a large number of treatment centers for this ailment will increase market share over the forecast period.

Market Competition

Key players in the Klinefelter syndrome therapeutics market are Hoffmann-La Roche Ltd., Takeda Pharmaceutical Company Limited, Kyowa Kirin Co., Ltd, Pfizer Inc., AstraZeneca, AbbVie, Inc., Bausch Health Companies Inc., Bristol Myers Squibb Company, GSK Plc, Novartis AG, Viatris. Significant international pharma companies are researching the creation of numerous testosterone drugs, which will assist them to increase their market share. Some of the novel developments by key players are mentioned below:

Takeda Pharmaceutical Company Limited and Seagen Inc. declared that information from the Phase 3 ECHELON-1 clinical trial of an ADCETRIS® (brentuximab vedotin) plus chemotherapy combination would be introduced in a verbal meeting at the 59th American Society of Clinical Oncology (ASCO) Annual Meeting.
Pfizer Inc. introduced Testosterone Cypionate Injection in 2021 as a replacement therapy for males suffering from illnesses of endogenous testosterone deficiency or absence.

Key Companies Profiled

Hoffmann-La Roche Ltd.
Takeda Pharmaceutical Company Limited
Kyowa Kirin Co., Ltd
Pfizer Inc.
AstraZeneca
AbbVie, Inc.
Bausch Health Companies Inc.
Bristol Myers Squibb Company
GSK Plc
Novartis AG
Viatris

A Full Report Overview

Key Segments Profiled in the Klinefelter Syndrome Therapeutics Industry Report

By Therapeutics:

Testosterone Replacement Therapy
Fertility Treatment
Surgeries
Hormone Treatment
Others

By Application:

Hospitals
Specialty Clinics
Others

By Distribution Channel:

Hospital Pharmacy
Retail Pharmacy
Online Pharmacies
Others

By Region:

North America
Europe
Asia Pacific
Latin America
Middle East and Africa

Author By:

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Marburg Virus Disease Therapeutics Market Projected to Reach USD 155 Million by 2033 at a 5.5% CAGR

The global Marburg Virus Disease Therapeutics Market is anticipated to achieve a market value of USD 90.74 million in 2023, with projections indicating growth to USD 155 million by 2033. This represents a compound annual growth rate (CAGR) of 5.5% during the forecast period from 2023 to 2033.

The growth of the Marburg virus disease therapeutics market is primarily driven by the increasing prevalence of the Marburg virus across various geographical regions. As healthcare systems recognize the critical need for effective treatments and therapeutics, demand for Marburg virus disease therapeutics has demonstrated a CAGR of 4.1% during the historical period from 2018 to 2022.

Key Market Insights:

Projected Market Value for 2023: US$ 90.74 million
Anticipated Market Value by 2033: US$ 155 million
CAGR (2023-2033): 5.5%
Historical CAGR (2018-2022): 4.1%

The rising incidence of Marburg virus disease, particularly in endemic regions, underscores the urgent need for effective therapeutic interventions. This growing demand is prompting pharmaceutical companies and research institutions to invest in the development of innovative therapies to combat this severe viral infection.

As the global healthcare community mobilizes to address the challenges posed by emerging viral threats, the Marburg virus disease therapeutics market is expected to expand significantly. Continued research and development efforts, coupled with increasing awareness of the disease, will further enhance the market’s growth potential over the coming decade.

iddle East and Africa along with North America are the two major reasons contributing to the growth of the Marburg virus diseases therapeutics market. This is owing to the increasing cases of Marburg virus in Middle East and Africa whereas on the other hand, the strong presence of key players in North America is investing in research and development for Marburg virus diseases therapeutics.

Key Takeaways from the Market Study

The hospitals segment is expected to hold 45% of the market share in 2023 for Marburg virus disease therapeutics market.
The Marburg virus disease therapeutics market is expected to grow at a value of 5.5% CAGR for forecast period 2023-2033.
North America is expected to possess 43% market share for Marburg virus disease therapeutics market in 2023.
Asia Pacific Marburg virus disease therapeutics market size is expected to possess 39% market share in 2023.

“The increasing prevalence of Marburg virus disease along with investment in efforts for research and development for innovating therapeutics is creating lucrative opportunities for the market,”states an FMI analyst.

Market Competition

Key players in the Marburg virus disease therapeutics market are Amicus Therapeutics, Inc, Alexion Pharmaceuticals, Inc, BioCryst Pharmaceuticals, Bavarian Nordic, Bio-Rad Laboratories, Inc, AlphaVax, GW Pharmaceuticals plc, Takeda Pharmaceutical Company Limited, Alexion Pharmaceuticals, Inc, Mapp Biopharmaceutical, Collaborations Pharmaceuticals, Inc, Emergent BioSolutions Inc, BioMarin and Sarepta Therapeutics, Alkido Pharma, Biofactura

BioCryst Pharmaceuticals, a key player in the Marburg virus disease therapeutics market is focusing on undertaking research and development for understanding the nature of the virus and innovating therapeutic treatments for the same.
Bio-Rad Laboratories, Inc, another key player in the Marburg virus disease therapeutics market is integrating technology to understand the ailment and offering medication for treating the virus.

Key Companies Profiled

Amicus Therapeutics Inc.
Alexion Pharmaceuticals Inc.
BioCryst Pharmaceuticals
Bavarian Nordic
Bio-Rad Laboratories, Inc.
AlphaVax
GW Pharmaceuticals Plc
Takeda Pharmaceutical Company Limited
Mapp Biopharmaceutical
Collaborations Pharmaceuticals Inc.
Emergent BioSolutions Inc.
BioMarin and Sarepta Therapeutics
Alkido Pharma
Biofactura

A Full Report Overview

Key Segments Profiled in the Marburg Virus Disease Therapeutics Industry Survey

By Drug Classification:

Antiemetic
Nitro-glycerine
Loperamide
Antibiotics
Others

By Route of Administration:

Injectable
Oral
Parenteral

By End Users:

Hospitals
Specialty Clinics
Ambulatory Surgical Centres
Others

By Distribution Channel:

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

By Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa

Author By:

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Durable Medical Equipment Rental Market Projected to Reach USD 47 Billion by 2033 at a 5.7% of CAGR

Global Durable Medical Equipment Rental Industry

A newly released analysis report by Future Market Insights reveals that the Durable Medical Equipment (DME) Rental Market generated a revenue of USD 25.7 billion in 2022. With a compound annual growth rate (CAGR) of 5.7% expected from 2023 to 2033, the market is projected to reach a valuation of USD 47 billion by the end of the forecast period.

Hospitals are anticipated to be the largest revenue-generating segment within the DME rental market, with a projected growth rate of over 5.7% from 2023 to 2033. The increasing demand for medical equipment rentals in hospital settings is driven by several factors, including the need for cost-effective healthcare solutions and the rising prevalence of chronic diseases that require long-term management.

Key Market Insights:

Market Revenue in 2022: US$ 25.7 billion
Projected Market Value by 2033: US$ 47 billion
CAGR (2023-2033): 5.7%
Key Growth Segment: Hospitals, projected to grow at over 5.7% CAGR

The growth of the Durable Medical Equipment Rental Market is attributed to the increasing acceptance of rental services over purchasing equipment, especially in the context of budget constraints faced by healthcare facilities. Additionally, advancements in technology and product offerings are enhancing the efficiency and effectiveness of medical equipment rentals, further driving market expansion.

As the healthcare landscape continues to evolve, the DME rental market is expected to play a critical role in facilitating patient care while optimizing operational costs for healthcare providers. The rising trend of home healthcare services and outpatient care is also contributing to the growing demand for durable medical equipment rentals.

Despite predicted and exponential growth, healthcare operators continue to struggle to find a sustainable financing alternative to invest in cutting-edge technology and equipment in order to meet the demands of an increasingly demanding customer base. Renting medical equipment could be the next big thing in the global healthcare business, providing cost-effective and economical options during challenging economic times.

The absence of uniform regulatory criteria for medical equipment rental services, as well as high costs, are expected to limit the industry’s expansion. Furthermore, it has been discovered that few medical gadgets come with insurance, which will stymie the growth of the worldwide rental market for medical equipment.

In 2022, North America led the market. This is because of the country’s strong healthcare system and government support for privately operated hospitals, clinics, and diagnostic services.

As per the Durable Medical Equipment Rental Market research by Future Market Insights – a market research and competitive intelligence provider, historically, from 2018 to 2022, the value of the Durable Medical Equipment Rental Market increased at around 5.1% CAGR.

Despite projected and exponential expansion, operators in the healthcare industry continue to struggle to find a sustainable financing alternative to invest in cutting-edge technology and equipment to keep up with an increasingly demanding client base. Rental medical equipment might be the next big thing in the global healthcare market, giving economical and cost-effective choices during difficult economic times.

As technology improves and the need for capital advances, providers struggle with finances. It becomes difficult to handle the equipment and finance them. Hospitals use rental equipment to deal with the capital crunch. Equipment integration, recalls, and reductions in reimbursement, are other factors that shift the focus from acquiring medical devices to renting them for use.

Competitive Analysis

Some of the key players operating in the medical equipment rental market include Hill-Rom Holdings Inc., Stryker Corporation, Getinge AB, Siemens Financial Services Inc, Nunn’s Home Medical Equipment, Westside Medical Supply, Universal Hospital Services, Inc., Woodley Equipment Company Ltd., GE Healthcare, C.N.Y. Medical Products Inc., All American Medical Supply Corp., and Homepro Medical Supplies, LLC.

Some of the recent developments of key Durable Medical Equipment Rental providers are as follows:

In June 2020, MedOne Company announced the launch of a new facility in North Carolina. The USA, for the rental and service of medical equipment.
In March 2020, Med-Equip announced the acquisition of Martab’s equipment management services. The acquisition is being carried out to provide rentals of custom-made gadgets such as home testing kits.

Similarly, recent developments related to companies in the Durable Medical Equipment Rental Market have been tracked by the team at Future Market Insights, which are available in the full report.

A Full Report Overview

Market Segments Covered in Durable Medical Equipment Rental Market Analysis

By Application:

Personal Mobility Devices
Bathroom Safety and Medical Furniture
Monitoring and Therapeutic Devices

By End Use:

Personal/Homecare
Institutes and laboratories
Hospitals

By Region:

North America
Latin America
Europe
APAC
Middle East and Africa (MEA)

Author By:

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Thrombocytopenia Treatment Market Expected to Reach USD 10 Billion by 2033, Growing at a CAGR of 5.2%

Global Thrombocytopenia Treatment Industry

The global Thrombocytopenia Treatment Market is projected to experience significant growth, with an anticipated compound annual growth rate (CAGR) of 5.2% from 2023 to 2033. The market is expected to reach a valuation of USD 10 billion by 2033, rising from USD 6 billion in 2023.

This growth is primarily driven by increasing morbidity and mortality rates associated with thrombocytopenia, affordable treatment options, and a growing awareness of the condition and its management. Thrombocytopenia, characterized by a low platelet count, can lead to serious health complications, necessitating effective treatment strategies.

Key Market Insights:

Projected Market Value for 2023: US$ 6 billion
Anticipated Market Value by 2033: US$ 10 billion
CAGR (2023-2033): 5.2%

Several factors are contributing to the expansion of the thrombocytopenia treatment market, including enhanced diagnostic capabilities, the development of novel therapies, and an increase in healthcare access. As awareness of thrombocytopenia grows, patients and healthcare providers are better equipped to manage the condition, leading to improved outcomes.

The rising demand for cost-effective treatment options is also playing a significant role in market growth. As pharmaceutical companies innovate and develop affordable therapies, they are meeting the needs of a broader patient population, which is crucial for addressing the challenges posed by thrombocytopenia.

Blood clots are due to platelets in the blood. Thrombocytopenia is defined as an abnormally low platelet count in the blood due to the presence of any illness or ailment. Individuals with thrombocytopenia have delayed or no blood clotting. Because of the high prevalence of thrombocytopenia and growing knowledge of treatment alternatives, the worldwide thrombocytopenia treatment market is likely to grow considerably in the near future.

Thrombocytopenia symptoms include nosebleeds, bruises, redness, and bleeding in the gums and mouth. Thrombocytopenia is discovered using tests such as a complete blood count (CBC) and a blood clotting study. Furthermore, biopsy and bone marrow aspiration are used to diagnose thrombocytopenia. According to a study published in Professional Med J in 2014 titled Incidence of Thrombocytopenia, the prevalence of thrombocytopenia is greater in persons aged 60 years and older who had non-cirrhotic liver disease. However, rapid discovery, along with the capacity to clone thrombopoietin, has resulted in novel therapeutic worldwide treatment options.

Market Competition

The thrombocytopenia treatment industry has experienced potential clinical breakthroughs as a result of ongoing guidelines changes. The 2018 American Society of Hematology (ASH) Guideline recommended a variety of alternative anticoagulant alternatives for doctors to consider.

Current practice recommendations in industrialized countries have prompted the development of novel thrombin inhibitors and immunoassays. This has increased therapy possibilities for acute thrombocytopenia treatment. Top players intend to introduce new anticoagulants to improve healthcare team outcomes. Manufacturers of assays and pharmaceuticals are focusing on lowering the probability of thromboembolic consequences.

Key players in the thrombocytopenia treatment market are 3SBio Inc., Amgen Inc., Takeda Pharmaceutical Company, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eisai Co., Ltd., Hansa Medical AB, Intas Pharmaceuticals Ltd. and Merck & Co., Inc.

Recent Developments:

In December 2021, Horizon Therapeutics Plc’s board of directors and Amgen Inc.’s board of directors announced that they have agreed on the terms of a cash offer for the Company by Pillartree Limited (Acquirer Sub), a newly formed private limited company wholly owned by Amgen, which is unanimously recommended by the Company Board and pursuant to which Acquirer Sub will acquire the entire issued and to be issued
In December 2020, Sunshine Guojian Pharmaceutical (Shanghai) Co. Ltd., a subsidiary of 3SBio Inc., and Verseau Therapeutics, Inc. announced the selection of a monoclonal antibody targeting VSIG4 as a license program under their partnership arrangement aimed at the creation and commercialization of novel monoclonal antibodies in the field of immuno-oncology for a variety of cancers.

Key Companies Profiled:

3SBio Inc.
Amgen Inc.
Takeda Pharmaceutical Company
Bayer AG
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Eisai Co., Ltd.
Hansa Medical AB
Intas Pharmaceuticals Ltd.
Merck & Co. Inc.

A Full Report Overview

Key Segments Profiled in the Thrombocytopenia Treatment Industry Survey

By Drug Class:

Glucocorticoids
Lysosomal Enzyme
Platelet Stimulating Agent

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Region:

North America
Latin America
Europe
Asia Pacific
Middle East & Africa

Author By:

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube